| Oct 15 |
XOMA Royalty's Preferred Shares: High-Yield Dividends From Biotech Royalties
|
| Sep 23 |
Zevra’s MIPLYFFA™ (arimoclomol) Receives Approval from U.S. Food and Drug Administration for Use in Patients with Niemann-Pick Disease Type C (NPC)
|
| Sep 23 |
XOMA Royalty Declares Quarterly Preferred Stock Dividends
|
| Sep 10 |
High Growth Tech Stocks In The United States To Watch
|
| Sep 4 |
XOMA Royalty to Present at Upcoming Investor Conferences in September
|
| Aug 18 |
Party Time: Brokers Just Made Major Increases To Their XOMA Royalty Corporation (NASDAQ:XOMA) Earnings Forecasts
|
| Aug 14 |
XOMA Royalty Second Quarter 2024 Earnings: Beats Expectations
|
| Aug 13 |
XOMA Royalty (XOMA) Reports Q2 Loss, Tops Revenue Estimates
|
| Aug 13 |
XOMA GAAP EPS of $0.84, revenue of $11.1M
|
| Aug 13 |
XOMA Royalty: Q2 Earnings Snapshot
|
